Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues
This article was originally published in The Tan Sheet
Executive Summary
Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups
You may also be interested in...
Regulatory News In Brief
Ephedrine-tainted herbals recalled
Supplement AERs Require Less Forgiving Risk/Benefit Calculation - FDA
FDA applies a lower tolerance for risk in evaluating serious adverse event reports for dietary supplements than for drug AERs because of the "uncertainty" surrounding supplement products, an agency official says
Hydroxycut Recall Sheds Light On Pros And Cons Of AER System
Identifying possible risks linked to dietary supplements - such as the recalled line of Hydroxycut weight-loss products - is challenging because FDA generally works with post-market information, an agency executive said